<DOC>
	<DOCNO>NCT00390715</DOCNO>
	<brief_summary>study value cytogenetics monitor residual minimum disease standard treatment acute myeloblastic leukemia .</brief_summary>
	<brief_title>Treatment Acute Myeloblastic Leukemia Younger Patients</brief_title>
	<detailed_description>The treatment scheme purely welfare therefore require approval ethical committee application . It gather basic idea present treatment AML , optional induction accord preference center daunorubicin Idarubicin ( x3 ) associate AraC ( x7 ) . The patient reach CR consolidate identical cycle use one induction . Later ( pte identical donor HLA , much doctor preference option ) receive allogenic transplant . The patient reach CR receive two intensification , one AraC intermediate dose contain another one autologous transplant , previous preparation Busulf√°n , Etoposide AraC . Later antileucemic treatment suspend possible relapse . This scheme treatment accompany valuation quality CR traditional morphology , Immunocytometry molecular genetic study pursuit residual minimum disease ( EMR ) use technique .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Age &lt; =65 year . ECOG &lt; =3 . AML new diagnose . Consent chemotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Acute Myeloblastic Leukemia</keyword>
</DOC>